Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors (Q33939069)

30 July 2017

Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors (English)

1 reference

30 July 2017

1 reference

Bavithra Nathan

1

1 reference

30 July 2017

Jake Bayley

series ordinal

2

1 reference

30 July 2017

Laura Waters

series ordinal

3

1 reference

30 July 2017

Frank A Post

series ordinal

4

1 reference

30 July 2017

3 September 2013

1 reference

Infectious diseases and therapy

30 July 2017

1 reference

30 July 2017

2

1 reference

30 July 2017

2

1 reference

30 July 2017

111-122

1 reference

https://scigraph.springernature.com/pub.10.1007/s40121-013-0013-7

30 July 2017

0 references

cites work

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Ritonavir-boosted protease inhibitors in HIV therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Recent developments in HIV and the kidney

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40121-013-0013-7

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4108106

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25134475

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40121-013-0013-7

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference